Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: Yahoo! Finance
Reported EPS is $-0.66, expectations were $-0.86. LSTA isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Welcome to the Lisata Therapeutics Full Year 2023 Financial Results and Business Update Conference Call. [Operator Instructions]. As a reminder, this call is being recorded today, February 29, 2024. I will now turn the call over to John Menditto, Vice President of Investor Relations, and Corporate Communications at Lisata. Please go ahead, sir. John Menditto: Thank you, operator, and good afternoon, everyone. Welcome to Lisata's Full Year 2023 Conference Call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President, and Chief Executive Officer; Dr. Kristen Buck Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Vice President of Finance and Treasury. Shortly before this call, we iss
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewswire
- Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma [Yahoo! Finance]Yahoo! Finance
LSTA
Earnings
- 5/9/23 - Beat
LSTA
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- 4/24/24 - Form 3
- LSTA's page on the SEC website